Bentley Systems Bolsters Cesium with Reality Modeling Capabilities, Brings Geospatial Context to Infrastructure Engineering
Bentley advances its open platform for the built and natural environment
(Bentley Systems’ Year in Infrastructure 2025) – Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced the availability of reality modeling services in Cesium, advancing its open platform for the built and natural environment. It also unveiled geospatial capabilities for project delivery and asset performance and a new immersive engagement application for infrastructure teams and stakeholders, all powered by Cesium.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015286327/en/

Bentley announced the availability of reality modeling services in Cesium, advancing its open platform for the built and natural environment. (Image courtesy of Bentley Systems)
Since acquiring Cesium a year ago, Bentley has made significant progress in integrating technologies from both companies, powering its own products and empowering developers to build applications that visualize infrastructure data in real time and in full geospatial context.
“Our vision for infrastructure engineering is built on openness,” said Patrick Cozzi, Bentley’s chief platform officer. “With the integration of iTwin and Cesium capabilities, we are creating the open platform for the built and natural environment—providing all the necessary data for infrastructure professionals to design, build, and operate in a real-world context.”
Adding reality modeling and AI-powered analysis to Cesium
Bentley has added reality modeling services from iTwin Capture to Cesium ion, creating a complete, automated pipeline from data capture through geospatial visualization. iTwin Capture creates engineering-grade reality models from imagery and applies AI-powered feature detection, while Cesium ion allows developers to create and host content in the cloud to power 3D geospatial applications.
With the new reality modeling capabilities, Cesium ion can create detailed 3D visualizations—reality meshes, point clouds, and Gaussian splats—directly from imagery, annotated by AI, ready to stream within applications using open standards. Creating an accurate, engineering-grade digital model of the existing built and natural environment and offering it as rich 3D geospatial context allows infrastructure professionals to make better informed decisions throughout the infrastructure lifecycle.
"Being able to generate photogrammetry, point clouds, and Gaussian splats as 3D Tiles from drone imagery, stream them seamlessly to the web, and analyze the point clouds is a major milestone,” said Osarodion Victory Igbinobaro, co-founder and CEO of AERO AI, a Cesium user. “This release brings end-to-end 3D reality modeling into one accessible, high-performance pipeline.”
The reality modeling capabilities in Cesium ion will be generally available before the end of 2025.
Enhancing project delivery and asset performance with geospatial context
Cesium capabilities are also enhancing Bentley’s product portfolio, bringing geospatial context to Bentley Open Applications and Bentley Infrastructure Cloud.
MicroStation 2025, the latest release of Bentley’s CAD software for infrastructure design, introduces support for 3D Tiles via Cesium. Engineers can now seamlessly integrate any 3D Tiles content, including Google Photorealistic 3D Tiles and their own high-fidelity reality data, directly into their design projects. This reduces the need to manually model existing conditions, accelerating project setup and allowing teams to focus on designing solutions. These same capabilities are coming to Bentley Open Applications built on MicroStation, for designing roads, railways, bridges, and more.
Cesium is also powering the geospatial experience in Bentley Infrastructure Cloud Connect, Bentley’s unified environment to connect data and people across the infrastructure lifecycle. With this geospatial context, also featuring Google Photorealistic 3D Tiles, users can navigate more intuitively across and within their projects and assets available in Bentley Infrastructure Cloud.
Introducing iTwin Engage
Bentley also announced iTwin Engage, which enables infrastructure teams and their stakeholders to engage immersively with digital twins of future and existing infrastructure assets.
Engineers often need to create immersive, photorealistic renderings to present their design work. Traditionally, this process is slow and inefficient, requiring specialized skills and resulting in static visuals that quickly become outdated as the design models evolve. With iTwin Engage, powered by Cesium and game engine technology, anyone can build impactful, narrative-driven content that brings projects and assets to life. Experiences are automatically generated, always current thanks to a live connection to the digital twin, and interactive—enabling not only design reviews, but also digital rehearsals for construction, immersive remote inspections, and more.
“The opportunity to present and communicate the project plan through iTwin Engage, in such an appealing manner, is fantastic,” said Simon Beards, principal planner, Laing O’Rourke, a participant in an early access program. “The greater the involvement the team has on the plan, the more likely there is a chance of success, as it supports a more collaborative way of engineering improvements.”
iTwin Engage will be in limited availability by the end of 2025.
# # #
About Bentley Systems
Around the world, infrastructure professionals rely on software from Bentley Systems to help them design, build, and operate better and more resilient infrastructure for transportation, water, energy, cities, and more. Founded in 1984 by engineers for engineers, Bentley is the partner of choice for engineering firms and owner-operators worldwide, with software that spans engineering disciplines, industry sectors, and all phases of the infrastructure lifecycle. Through our digital twin solutions, we help infrastructure professionals unlock the value of their data to transform project delivery and asset performance.
© 2025 Bentley Systems, Incorporated. Bentley, the Bentley logo, Cesium, Cesium ion, 3D Tiles, iTwin, Bentley Infrastructure Cloud, MicroStation, Bentley Open Applications, iTwin Capture, and iTwin Engage are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251015286327/en/



Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom